focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-UK approves COVID-19 boosters but final decision on programme still pending

Thu, 09th Sep 2021 13:04

* MHRA gives go-ahead for Pfizer, AZ booster shots

* Final decision on programme still pending

* Debate over if and when boosters will be needed
(Adds detail, context)

By Alistair Smout

LONDON, Sept 9 (Reuters) - Britain's medical regulator on
Thursday gave the go-ahead for Pfizer and AstraZeneca's
COVID-19 vaccine to be used as booster shots, but said
any decision to proceed with a booster programme was for others
to make.

Britain's Joint Committee for Vaccination and Immunisation
(JCVI) is discussing whether booster shots for the elderly and
vulnerable are needed, with planning underway for a booster
programme that could begin this month.

The final decision on whether there should be booster shots
is for the government, but the regulator's decision clears one
hurdle along that path.

"I am pleased to confirm that the COVID-19 vaccines made by
Pfizer and AstraZeneca can be used as safe and effective booster
doses," said June Raine, chief executive of the Medicines and
Healthcare products Regulatory Agency (MHRA).

"It will now be for the (JCVI) to advise on whether booster
jabs will be given."

Whether booster vaccinations are needed is an open question,
especially as the likes of Britain and the United States are
planning third doses when COVID continues to kill unvaccinated
people around the world.

Pfizer has said that it believes a third shot of vaccine
will be needed to maintain protection, although executives at
AstraZeneca, who are not making a profit on the vaccine during
the pandemic, have stressed the need to wait for evidence and
not pursue booster programmes that are not needed.

Earlier on Thursday, JCVI member Adam Finn said that it
wasn't clear that protection was waning against severe disease,
and that a mistimed booster programme might cause more problems.

"Getting the timing right is one of several things that we
need to get right. You could conceivably run into a position
where you're immunising a lot of people when they don't actually
need to be," he told BBC radio.

"(Then) if the vaccines do wane, then they will wane earlier
than they would have done if you'd immunised them when they did
need (a booster)."
(Reporting by Alistair Smout; editing by William James)

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.